GrippeCanadaV3, Main, Exploration, bibRecord, 000504

Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada.

Identifieur interne : 000504 ( Main/Exploration ); précédent : 000503; suivant : 000505

Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada.

Auteurs : Jean Longtin [Canada] ; Samir Patel ; Alireza Eshaghi ; Ernesto Lombos ; Rachel Higgins ; David Alexander ; Romy Olsha ; John Doyle ; Dat Tran ; Alicia Sarabia ; Christine Lee ; Nathalie Bastien ; Yan Li ; Donald Low ; Guy Boivin ; Jonathan Gubbay

Source :

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology [ 1873-5967 ] ; 2011.

RBID : pubmed:21251873

Descripteurs français

KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Antiviraux (pharmacologie), Enfant, Femelle, Grippe humaine (virologie), Humains, Jeune adulte, Mutation faux-sens, Mâle, Ontario, Oséltamivir (pharmacologie), Protéines virales (génétique), Résistance virale aux médicaments, Sialidase (génétique), Sous-type H1N1 du virus de la grippe A (), Sous-type H1N1 du virus de la grippe A (isolement et purification), Substitution d'acide aminé (génétique).
MESH :
- génétique : Protéines virales, Sialidase, Substitution d'acide aminé.
- isolement et purification : Sous-type H1N1 du virus de la grippe A.
- pharmacologie : Antiviraux, Oséltamivir.
- virologie : Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Femelle, Humains, Jeune adulte, Mutation faux-sens, Mâle, Ontario, Résistance virale aux médicaments, Sous-type H1N1 du virus de la grippe A.

English descriptors

KwdEn :
- Adolescent, Adult, Amino Acid Substitution (genetics), Antiviral Agents (pharmacology), Child, Drug Resistance, Viral, Female, Humans, Influenza A Virus, H1N1 Subtype (drug effects), Influenza A Virus, H1N1 Subtype (isolation & purification), Influenza, Human (virology), Male, Middle Aged, Mutation, Missense, Neuraminidase (genetics), Ontario, Oseltamivir (pharmacology), Viral Proteins (genetics), Young Adult.
MESH :
- chemical , genetics : Neuraminidase, Viral Proteins.
- chemical , pharmacology : Antiviral Agents, Oseltamivir.
- geographic : Ontario.
- drug effects : Influenza A Virus, H1N1 Subtype.
- genetics : Amino Acid Substitution.
- isolation & purification : Influenza A Virus, H1N1 Subtype.
- virology : Influenza, Human.
- Adolescent, Adult, Child, Drug Resistance, Viral, Female, Humans, Male, Middle Aged, Mutation, Missense, Young Adult.

Abstract

BACKGROUND

Oseltamivir resistance-associated H275Y mutation in the neuraminidase (NA) gene of pandemic influenza A (H1N1) 2009 was occasionally reported worldwide during the 2009-2010 influenza season. A significant proportion of those were found in immunocompromised or severely ill persons. This phenomenon remains infrequent and clear recommendations for resistance testing are lacking.

OBJECTIVES

Present the suggested clinical selection criteria for antiviral susceptibility testing for influenza in Canada and to describe the Ontarian experience during the 2009-2010 influenza season.

STUDY DESIGN

Using a defined algorithm, we prospectively screened for OsR with pyrosequencing and phenotypic testing during the 2009-2010 influenza season. Zanamivir resistance was screened using phenotypic and sequencing technique on selected occasions. Clinical data was gathered for the resistant cases.

RESULTS

A total of 804 clinical H1N1 (2009) positive samples from Ontario were screened for oseltamivir resistance between June 2009 and March 2010. We identified oseltamivir resistance in 5 (0.6%) distinct patients aged 9-62 years. All the resistant strains bore the H275Y mutation. Susceptibility to zanamivir was maintained in all of them. Three patients harboring oseltamivir resistant strain were intensive care unit patients and four were immunocompromised. All were tested for susceptibility because of a repeat positive result for influenza A PCR.

CONCLUSION

Oseltamivir resistance was not frequent during the 2009-2010 influenza season but was identified with a systematic and prospective approach to resistance testing. In order to be as sensitive as possible in the detection of those few cases, we report the suggested indications for antiviral susceptibility testing in Canada.

DOI: 10.1016/j.jcv.2010.12.007
PubMed: 21251873

Affiliations:

Canada

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000564
to stream Main, to step Curation: 000564

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada.</title>
<author><name sortKey="Longtin, Jean" sort="Longtin, Jean" uniqKey="Longtin J" first="Jean" last="Longtin">Jean Longtin</name>
<affiliation wicri:level="1"><nlm:affiliation>Ontario Agency for Health Protection and Promotion, Public Health Laboratories, 81 Resources Road, Toronto M9P 3T1, Canada. Jean.longtin@chuq.qc.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Ontario Agency for Health Protection and Promotion, Public Health Laboratories, 81 Resources Road, Toronto M9P 3T1</wicri:regionArea>
<wicri:noRegion>Toronto M9P 3T1</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Patel, Samir" sort="Patel, Samir" uniqKey="Patel S" first="Samir" last="Patel">Samir Patel</name>
</author>
<author><name sortKey="Eshaghi, Alireza" sort="Eshaghi, Alireza" uniqKey="Eshaghi A" first="Alireza" last="Eshaghi">Alireza Eshaghi</name>
</author>
<author><name sortKey="Lombos, Ernesto" sort="Lombos, Ernesto" uniqKey="Lombos E" first="Ernesto" last="Lombos">Ernesto Lombos</name>
</author>
<author><name sortKey="Higgins, Rachel" sort="Higgins, Rachel" uniqKey="Higgins R" first="Rachel" last="Higgins">Rachel Higgins</name>
</author>
<author><name sortKey="Alexander, David" sort="Alexander, David" uniqKey="Alexander D" first="David" last="Alexander">David Alexander</name>
</author>
<author><name sortKey="Olsha, Romy" sort="Olsha, Romy" uniqKey="Olsha R" first="Romy" last="Olsha">Romy Olsha</name>
</author>
<author><name sortKey="Doyle, John" sort="Doyle, John" uniqKey="Doyle J" first="John" last="Doyle">John Doyle</name>
</author>
<author><name sortKey="Tran, Dat" sort="Tran, Dat" uniqKey="Tran D" first="Dat" last="Tran">Dat Tran</name>
</author>
<author><name sortKey="Sarabia, Alicia" sort="Sarabia, Alicia" uniqKey="Sarabia A" first="Alicia" last="Sarabia">Alicia Sarabia</name>
</author>
<author><name sortKey="Lee, Christine" sort="Lee, Christine" uniqKey="Lee C" first="Christine" last="Lee">Christine Lee</name>
</author>
<author><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name>
</author>
<author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
</author>
<author><name sortKey="Low, Donald" sort="Low, Donald" uniqKey="Low D" first="Donald" last="Low">Donald Low</name>
</author>
<author><name sortKey="Boivin, Guy" sort="Boivin, Guy" uniqKey="Boivin G" first="Guy" last="Boivin">Guy Boivin</name>
</author>
<author><name sortKey="Gubbay, Jonathan" sort="Gubbay, Jonathan" uniqKey="Gubbay J" first="Jonathan" last="Gubbay">Jonathan Gubbay</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21251873</idno>
<idno type="pmid">21251873</idno>
<idno type="doi">10.1016/j.jcv.2010.12.007</idno>
<idno type="wicri:Area/Main/Corpus">000564</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000564</idno>
<idno type="wicri:Area/Main/Curation">000564</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000564</idno>
<idno type="wicri:Area/Main/Exploration">000564</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada.</title>
<author><name sortKey="Longtin, Jean" sort="Longtin, Jean" uniqKey="Longtin J" first="Jean" last="Longtin">Jean Longtin</name>
<affiliation wicri:level="1"><nlm:affiliation>Ontario Agency for Health Protection and Promotion, Public Health Laboratories, 81 Resources Road, Toronto M9P 3T1, Canada. Jean.longtin@chuq.qc.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Ontario Agency for Health Protection and Promotion, Public Health Laboratories, 81 Resources Road, Toronto M9P 3T1</wicri:regionArea>
<wicri:noRegion>Toronto M9P 3T1</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Patel, Samir" sort="Patel, Samir" uniqKey="Patel S" first="Samir" last="Patel">Samir Patel</name>
</author>
<author><name sortKey="Eshaghi, Alireza" sort="Eshaghi, Alireza" uniqKey="Eshaghi A" first="Alireza" last="Eshaghi">Alireza Eshaghi</name>
</author>
<author><name sortKey="Lombos, Ernesto" sort="Lombos, Ernesto" uniqKey="Lombos E" first="Ernesto" last="Lombos">Ernesto Lombos</name>
</author>
<author><name sortKey="Higgins, Rachel" sort="Higgins, Rachel" uniqKey="Higgins R" first="Rachel" last="Higgins">Rachel Higgins</name>
</author>
<author><name sortKey="Alexander, David" sort="Alexander, David" uniqKey="Alexander D" first="David" last="Alexander">David Alexander</name>
</author>
<author><name sortKey="Olsha, Romy" sort="Olsha, Romy" uniqKey="Olsha R" first="Romy" last="Olsha">Romy Olsha</name>
</author>
<author><name sortKey="Doyle, John" sort="Doyle, John" uniqKey="Doyle J" first="John" last="Doyle">John Doyle</name>
</author>
<author><name sortKey="Tran, Dat" sort="Tran, Dat" uniqKey="Tran D" first="Dat" last="Tran">Dat Tran</name>
</author>
<author><name sortKey="Sarabia, Alicia" sort="Sarabia, Alicia" uniqKey="Sarabia A" first="Alicia" last="Sarabia">Alicia Sarabia</name>
</author>
<author><name sortKey="Lee, Christine" sort="Lee, Christine" uniqKey="Lee C" first="Christine" last="Lee">Christine Lee</name>
</author>
<author><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name>
</author>
<author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
</author>
<author><name sortKey="Low, Donald" sort="Low, Donald" uniqKey="Low D" first="Donald" last="Low">Donald Low</name>
</author>
<author><name sortKey="Boivin, Guy" sort="Boivin, Guy" uniqKey="Boivin G" first="Guy" last="Boivin">Guy Boivin</name>
</author>
<author><name sortKey="Gubbay, Jonathan" sort="Gubbay, Jonathan" uniqKey="Gubbay J" first="Jonathan" last="Gubbay">Jonathan Gubbay</name>
</author>
</analytic>
<series><title level="j">Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</title>
<idno type="eISSN">1873-5967</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Amino Acid Substitution (genetics)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Child</term>
<term>Drug Resistance, Viral</term>
<term>Female</term>
<term>Humans</term>
<term>Influenza A Virus, H1N1 Subtype (drug effects)</term>
<term>Influenza A Virus, H1N1 Subtype (isolation & purification)</term>
<term>Influenza, Human (virology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mutation, Missense</term>
<term>Neuraminidase (genetics)</term>
<term>Ontario</term>
<term>Oseltamivir (pharmacology)</term>
<term>Viral Proteins (genetics)</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Antiviraux (pharmacologie)</term>
<term>Enfant</term>
<term>Femelle</term>
<term>Grippe humaine (virologie)</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mutation faux-sens</term>
<term>Mâle</term>
<term>Ontario</term>
<term>Oséltamivir (pharmacologie)</term>
<term>Protéines virales (génétique)</term>
<term>Résistance virale aux médicaments</term>
<term>Sialidase (génétique)</term>
<term>Sous-type H1N1 du virus de la grippe A ()</term>
<term>Sous-type H1N1 du virus de la grippe A (isolement et purification)</term>
<term>Substitution d'acide aminé (génétique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Neuraminidase</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Oseltamivir</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ontario</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Amino Acid Substitution</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Protéines virales</term>
<term>Sialidase</term>
<term>Substitution d'acide aminé</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Oséltamivir</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Child</term>
<term>Drug Resistance, Viral</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mutation, Missense</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Enfant</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mutation faux-sens</term>
<term>Mâle</term>
<term>Ontario</term>
<term>Résistance virale aux médicaments</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Oseltamivir resistance-associated H275Y mutation in the neuraminidase (NA) gene of pandemic influenza A (H1N1) 2009 was occasionally reported worldwide during the 2009-2010 influenza season. A significant proportion of those were found in immunocompromised or severely ill persons. This phenomenon remains infrequent and clear recommendations for resistance testing are lacking.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b>
</p>
<p>Present the suggested clinical selection criteria for antiviral susceptibility testing for influenza in Canada and to describe the Ontarian experience during the 2009-2010 influenza season.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>STUDY DESIGN</b>
</p>
<p>Using a defined algorithm, we prospectively screened for OsR with pyrosequencing and phenotypic testing during the 2009-2010 influenza season. Zanamivir resistance was screened using phenotypic and sequencing technique on selected occasions. Clinical data was gathered for the resistant cases.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>A total of 804 clinical H1N1 (2009) positive samples from Ontario were screened for oseltamivir resistance between June 2009 and March 2010. We identified oseltamivir resistance in 5 (0.6%) distinct patients aged 9-62 years. All the resistant strains bore the H275Y mutation. Susceptibility to zanamivir was maintained in all of them. Three patients harboring oseltamivir resistant strain were intensive care unit patients and four were immunocompromised. All were tested for susceptibility because of a repeat positive result for influenza A PCR.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>Oseltamivir resistance was not frequent during the 2009-2010 influenza season but was identified with a systematic and prospective approach to resistance testing. In order to be as sensitive as possible in the detection of those few cases, we report the suggested indications for antiviral susceptibility testing in Canada.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21251873</PMID>
<DateCompleted><Year>2011</Year>
<Month>05</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5967</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>50</Volume>
<Issue>3</Issue>
<PubDate><Year>2011</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</Title>
<ISOAbbreviation>J. Clin. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada.</ArticleTitle>
<Pagination><MedlinePgn>257-61</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcv.2010.12.007</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Oseltamivir resistance-associated H275Y mutation in the neuraminidase (NA) gene of pandemic influenza A (H1N1) 2009 was occasionally reported worldwide during the 2009-2010 influenza season. A significant proportion of those were found in immunocompromised or severely ill persons. This phenomenon remains infrequent and clear recommendations for resistance testing are lacking.</AbstractText>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Present the suggested clinical selection criteria for antiviral susceptibility testing for influenza in Canada and to describe the Ontarian experience during the 2009-2010 influenza season.</AbstractText>
<AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Using a defined algorithm, we prospectively screened for OsR with pyrosequencing and phenotypic testing during the 2009-2010 influenza season. Zanamivir resistance was screened using phenotypic and sequencing technique on selected occasions. Clinical data was gathered for the resistant cases.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 804 clinical H1N1 (2009) positive samples from Ontario were screened for oseltamivir resistance between June 2009 and March 2010. We identified oseltamivir resistance in 5 (0.6%) distinct patients aged 9-62 years. All the resistant strains bore the H275Y mutation. Susceptibility to zanamivir was maintained in all of them. Three patients harboring oseltamivir resistant strain were intensive care unit patients and four were immunocompromised. All were tested for susceptibility because of a repeat positive result for influenza A PCR.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Oseltamivir resistance was not frequent during the 2009-2010 influenza season but was identified with a systematic and prospective approach to resistance testing. In order to be as sensitive as possible in the detection of those few cases, we report the suggested indications for antiviral susceptibility testing in Canada.</AbstractText>
<CopyrightInformation>Crown Copyright © 2010. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Longtin</LastName>
<ForeName>Jean</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Ontario Agency for Health Protection and Promotion, Public Health Laboratories, 81 Resources Road, Toronto M9P 3T1, Canada. Jean.longtin@chuq.qc.ca</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Patel</LastName>
<ForeName>Samir</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Eshaghi</LastName>
<ForeName>Alireza</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lombos</LastName>
<ForeName>Ernesto</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Higgins</LastName>
<ForeName>Rachel</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Alexander</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Olsha</LastName>
<ForeName>Romy</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Doyle</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tran</LastName>
<ForeName>Dat</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sarabia</LastName>
<ForeName>Alicia</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bastien</LastName>
<ForeName>Nathalie</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Low</LastName>
<ForeName>Donald</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Boivin</LastName>
<ForeName>Guy</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gubbay</LastName>
<ForeName>Jonathan</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2011</Year>
<Month>01</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>J Clin Virol</MedlineTA>
<NlmUniqueID>9815671</NlmUniqueID>
<ISSNLinking>1386-6532</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>20O93L6F9H</RegistryNumber>
<NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="C487630">NA protein, influenza A virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D024882" MajorTopicYN="Y">Drug Resistance, Viral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year>
<Month>10</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2010</Year>
<Month>12</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2010</Year>
<Month>12</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>1</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>1</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2011</Year>
<Month>5</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">21251873</ArticleId>
<ArticleId IdType="pii">S1386-6532(10)00494-4</ArticleId>
<ArticleId IdType="doi">10.1016/j.jcv.2010.12.007</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><noCountry><name sortKey="Alexander, David" sort="Alexander, David" uniqKey="Alexander D" first="David" last="Alexander">David Alexander</name>
<name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name>
<name sortKey="Boivin, Guy" sort="Boivin, Guy" uniqKey="Boivin G" first="Guy" last="Boivin">Guy Boivin</name>
<name sortKey="Doyle, John" sort="Doyle, John" uniqKey="Doyle J" first="John" last="Doyle">John Doyle</name>
<name sortKey="Eshaghi, Alireza" sort="Eshaghi, Alireza" uniqKey="Eshaghi A" first="Alireza" last="Eshaghi">Alireza Eshaghi</name>
<name sortKey="Gubbay, Jonathan" sort="Gubbay, Jonathan" uniqKey="Gubbay J" first="Jonathan" last="Gubbay">Jonathan Gubbay</name>
<name sortKey="Higgins, Rachel" sort="Higgins, Rachel" uniqKey="Higgins R" first="Rachel" last="Higgins">Rachel Higgins</name>
<name sortKey="Lee, Christine" sort="Lee, Christine" uniqKey="Lee C" first="Christine" last="Lee">Christine Lee</name>
<name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
<name sortKey="Lombos, Ernesto" sort="Lombos, Ernesto" uniqKey="Lombos E" first="Ernesto" last="Lombos">Ernesto Lombos</name>
<name sortKey="Low, Donald" sort="Low, Donald" uniqKey="Low D" first="Donald" last="Low">Donald Low</name>
<name sortKey="Olsha, Romy" sort="Olsha, Romy" uniqKey="Olsha R" first="Romy" last="Olsha">Romy Olsha</name>
<name sortKey="Patel, Samir" sort="Patel, Samir" uniqKey="Patel S" first="Samir" last="Patel">Samir Patel</name>
<name sortKey="Sarabia, Alicia" sort="Sarabia, Alicia" uniqKey="Sarabia A" first="Alicia" last="Sarabia">Alicia Sarabia</name>
<name sortKey="Tran, Dat" sort="Tran, Dat" uniqKey="Tran D" first="Dat" last="Tran">Dat Tran</name>
</noCountry>
<country name="Canada"><noRegion><name sortKey="Longtin, Jean" sort="Longtin, Jean" uniqKey="Longtin J" first="Jean" last="Longtin">Jean Longtin</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000504 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000504 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeCanadaV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:21251873
   |texte=   Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:21251873" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeCanadaV3

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 13:36:58 2020. Site generation: Sat Sep 26 07:06:42 2020

	Corpus GrippeCanadaV3
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Corpus GrippeCanadaV3

Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada.

Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki